QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 soon-to-be-acquired-cerevel-therapeutics-reveals-high-level-data-from-late-stage-parkinsons-disease-study

Discover toplines results of Cerevel Therapeutics' Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease treatment...

 why-is-ulcerative-colitis-focused-landos-biopharma-stock-trading-higher-on-monday

AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising...

 mizuho-maintains-neutral-on-cerevel-therapeutics-hldg-raises-price-target-to-45

Mizuho analyst Graig Suvannavejh maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral and raises the price targe...

 this-analyst-is-bullish-on-biohavens-approach-in-neuro-psych-space

Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion acro...

 ubs-bullish-on-this-depression-drug-maker-says-alzheimers-agitation-data-is-attractive-catalyst

UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. P...

 abbvie-lifts-long-term-outlook-for-new-immunology-drugs-even-as-q4-revenue-and-profit-fall

AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outloo...

 abbvies-transformational-2023-analyst-anticipates-growth-in-2024-amid-competitive-pressures

AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, st...

 5-biotech-stocks-that-should-be-on-investors-radar-as-jpmorgan-healthcare-conference-gets-underway-monday

The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even ...

 upward-trajectory-for-biotechpharma-ma-sector-trends-towards-pre-pandemic-levels-forecasts-positive-for-2024

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 bill...

 jp-morgan-maintains-neutral-on-cerevel-therapeutics-hldg-raises-price-target-to-45

JP Morgan analyst Jessica Fye maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral and raises the price target f...

 tesla-to-rally-around-38-here-are-10-top-analyst-forecasts-for-friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 jefferies-downgrades-cerevel-therapeutics-hldg-to-hold-raises-price-target-to-45

Jefferies analyst Michael Yee downgrades Cerevel Therapeutics Hldg (NASDAQ:CERE) from Buy to Hold and raises the price targe...

 td-cowen-downgrades-cerevel-therapeutics-hldg-to-market-perform-announces-45-price-target

TD Cowen analyst Joseph Thome downgrades Cerevel Therapeutics Hldg (NASDAQ:CERE) from Outperform to Market Perform and annou...

 abbvies-new-9b-neuroscience-space-deal-might-attract-ftc-scrutiny-analyst-signals

Wednesday, AbbVie Inc (NYSE: ABBV) agreed to acquire Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) for a total equity value ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION